Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 4/2020

01-10-2020 | Cytokines | Original article

Study on the expression of CD14 + CD16 + monocytes and VEGF in peripheral blood of patients with type 2 diabetes mellitus and diabetic macroangiopathy

Authors: Xue Zhou, Meng-Xue Yang, Jie Xu, Jie Yu, Bo Yang, Bo-Wen Sun, Fei Li, Qi-Hai Gong, Xiao-Yong Yan, Yi-Bin Yang, Mei Tian

Published in: International Journal of Diabetes in Developing Countries | Issue 4/2020

Login to get access

Abstract

Objectives

To study the expression of CD14 + CD16 + monocytes and VEGF and the levels of serum adiponectin and MCP-1 in peripheral blood of patients with type 2 diabetes mellitus (T2DM) and diabetic macroangiopathy to understand the possible mechanism of inflammatory immune response in T2DM and diabetic macroangiopathy.

Methods

Peripheral blood CD14 + CD16 + monocytes were detected by flow cytometry in 50 T2DM patients, 50 patients with diabetic macroangiopathy, and 20 healthy controls or normal controls who participated in outpatient physical examination, and used the Ficoll-Hypaque density gradient centrifugation isolated PBMC and quantitative PCR technology comparison between groups research object in the peripheral blood PBMC VEGF mRNA expression level. Serum levels of adiponectin and MCP-1 were measured by ELISA.

Results

Compared with normal control group (NGT), the fluorescence intensity of proinflammatory CD14 + CD16 + monocytes in simple T2DM group and T2DM combined with macroangiopathy group were significantly increased (p < 0.05), and T2DM combined with macroangiopathy group was significantly higher than T2DM group, the difference was statistically significant (p < 0.01). Moreover, the expression of VEGF mRNA in peripheral blood PBMCs, T2DM combined with macroangiopathy> T2DM patients> healthy volunteers, the differences were significant (p < 0.05). Compared with NGT group, the levels of serum adiponectin in T2DM group and T2DM combined with macroangiopathy group were significantly lower than those in NGT group (p < 0.01), and the levels of serum adiponectin, simple T2DM Group were lower than T2DM combined with macroangiopathy group (p < 0.05). The level of MCP-1 in serum compared with simple T2DM group and NGT group, T2DM combined with macroangiopathy group had statistically significant difference (p < 0.05). The serum level of MCP-1 in T2DM group was also higher than that in NGT group (p < 0.05). At the same time, we also found that the increase of CD14 + CD16 + monocytes was positively correlated with serum MCP-1 levels.

Conclusions

T2DM patients and T2DM combined with macroangiopathy patients have increased expression of VEGF and MCP-1 concentration in peripheral blood mononuclear cells. The increase of MCP-1 may increase the number of CD14 + CD16 + monocytes, which is involved in the chronic inflammation in patients with T2DM and T2DM combined with macroangiopathy, resulting in the occurrence and development of T2DM and its complications.
Literature
1.
go back to reference Yang M-X, Gan H, Shen Q, et al. Proportion of CD14+CD16+ monocyte s in peripheral blood from patients with type 2 diabetic mellitus and effect of LPS and IL-15 on expression of STAT5 in monocytes. Chin J Pathophysiol. 2012;28(1):136–41. Yang M-X, Gan H, Shen Q, et al. Proportion of CD14+CD16+ monocyte s in peripheral blood from patients with type 2 diabetic mellitus and effect of LPS and IL-15 on expression of STAT5 in monocytes. Chin J Pathophysiol. 2012;28(1):136–41.
2.
go back to reference Yang M-X, Gan H, Shen Q, et al. Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation. 2012;35(1):388–96.CrossRef Yang M-X, Gan H, Shen Q, et al. Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation. 2012;35(1):388–96.CrossRef
3.
go back to reference Yuan G-Y, Chen M-D. Progress in adiponectin receptor and signal transduction. Sect Endocrinol For Med Sci. 2004;24(z1):3–6. Yuan G-Y, Chen M-D. Progress in adiponectin receptor and signal transduction. Sect Endocrinol For Med Sci. 2004;24(z1):3–6.
4.
go back to reference Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55(6):1537–45.CrossRef Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes. 2006;55(6):1537–45.CrossRef
5.
go back to reference Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes:a systematic review and meta-analysis. JAMA. 2009;302(2):179–88.CrossRef Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes:a systematic review and meta-analysis. JAMA. 2009;302(2):179–88.CrossRef
6.
go back to reference Tie J, Desai J. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog. 2012;17(1):51–67.CrossRef Tie J, Desai J. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog. 2012;17(1):51–67.CrossRef
7.
go back to reference Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24(2):188–93.CrossRef Eichmann A, Simons M. VEGF signaling inside vascular endothelial cells and beyond. Curr Opin Cell Biol. 2012;24(2):188–93.CrossRef
8.
go back to reference Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S, et al. Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro. Oncol Lett. 2014;7(3):755–63.CrossRef Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S, et al. Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro. Oncol Lett. 2014;7(3):755–63.CrossRef
9.
go back to reference Carbajo-Pescador S, Ordoñez R, Benet M. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109(1):83–91.CrossRef Carbajo-Pescador S, Ordoñez R, Benet M. Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells. Br J Cancer. 2013;109(1):83–91.CrossRef
10.
go back to reference Li F-P, Li X-W, Yang M-X, et al. Expression of JAK2/STAT3 signaling pathway in human umbilical vein endothelial cells exposed to the serum of type 2 diabetic macroangiopathy patients. Acad J Second Mil Univ. 2016;37(4):452–6. Li F-P, Li X-W, Yang M-X, et al. Expression of JAK2/STAT3 signaling pathway in human umbilical vein endothelial cells exposed to the serum of type 2 diabetic macroangiopathy patients. Acad J Second Mil Univ. 2016;37(4):452–6.
Metadata
Title
Study on the expression of CD14 + CD16 + monocytes and VEGF in peripheral blood of patients with type 2 diabetes mellitus and diabetic macroangiopathy
Authors
Xue Zhou
Meng-Xue Yang
Jie Xu
Jie Yu
Bo Yang
Bo-Wen Sun
Fei Li
Qi-Hai Gong
Xiao-Yong Yan
Yi-Bin Yang
Mei Tian
Publication date
01-10-2020
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 4/2020
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-020-00809-4

Other articles of this Issue 4/2020

International Journal of Diabetes in Developing Countries 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine